脉冲电场消融治疗室性心律失常的美国多中心注册研究
评估PFA治疗室性心律失常的可行性、安全性与疗效。结果显示急性成功率较高,并发症发生率低,但室性早搏消融的远期疗效相对有限。
要点
- PFA治疗室性心律失常急性成功率高,并发症发生率低。
- 室速消融后12个月无复发率约61.5%,室早负荷降低≥80%者约58.3%。
- 二尖瓣装置附近消融未加重二尖瓣反流。
核心结论
- PFA治疗室性心律失常可行且急性有效,操作相关并发症发生率低。
- 室速消融远期结局可接受,室早消融远期疗效相对有限,需继续优化技术和能量释放策略。
研究设计与样本
- 患者包括室早13例、室速13例,中位随访365天。
主要发现
- 并发症发生率11.5%,包括一过性左束支传导阻滞1例和血管并发症2例。
- 未观察到血栓栓塞事件、心腔内血栓或急性肾损伤。
- 二尖瓣装置附近消融未加重二尖瓣反流,包括既往存在瓣膜病的患者。
- 随访期间1例患者出现需ICD电击的室速复发,室速消融后12个月无复发率估计为61.5%。
关键数值与推荐
- 主要可行性结局为成功将PFA损伤释放至预定靶点基质。
- 主要疗效结局包括急性操作成功、需ICD电击或多次抗心动过速起搏治疗的持续性室速复发、室早负荷降低≥80%。
- 安全性结局包括操作并发症、瓣膜功能、血栓栓塞事件、肾功能和传导障碍。
临床怎么用
- PFA可作为室性心律失常消融的一种急性有效且安全性可接受的方案。
- 室早消融的远期获益相对有限,临床决策需权衡预期获益。
局限性
- 需要更大样本的前瞻性研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Background Pulsed field ablation (PFA) is an emerging non-thermal ablation modality with proven safety in atrial arrhythmia ablation. However, data on its performance for ventricular arrhythmias (VA) remain limited. Objective To evaluate the feasibility, safety, and efficacy of PFA for complex VA in a multicenter real-world US registry. Methods This retrospective study included consecutive patients undergoing PFA for ventricular tachycardia (VT) or premature ventricular contractions (PVCs) at three Mayo Clinic centers (April 2024 to July 2025). The primary feasibility outcome was the successful delivery of PFA lesions to the intended target substrate. Primary efficacy outcomes included acute procedural success; sustained VT recurrence requiring implantable cardioverter-defibrillator (ICD) shocks or multiple antitachycardia pacing therapies; and ≥ 80% reduction in PVC burden. Safety outcomes included procedural complications, valvular function, thromboembolic events, renal function, and conduction disturbances. Results Twenty-six patients were included (13 PVC, 13 VT). Acute success was achieved in all VT ablations (69.2% complete; 30.8% partial) and in 92.3% of PVC ablations. Complications occurred in 11.5% of patients (transient LBBB [n = 1] and vascular complications [n = 2]). No thromboembolic events, intracardiac thrombus, or acute kidney injury were observed. Lesions near the mitral valve apparatus did not worsen mitral regurgitation, including in patients with pre-existing valve disease. After a median follow-up of 365 days, one patient experienced VT recurrence requiring ICD shocks. Estimated recurrence-free survival after VT ablation was 61.5% at 12 months; 58.3% of PVC patients achieved ≥ 80% burden reduction. Conclusion PFA for VA appears feasible and acutely effective, with a low rate of procedure-related complications. While acute success was high, long-term outcomes were acceptable for VT ablation and relatively modest for PVC ablation, highlighting the need for continued refinement of technology and energy-delivery strategies. Larger prospective studies are warranted.
引用
- Journal of Cardiovascular Electrophysiology:Feasibility, Safety, and Efficacy of Pulsed Field Ablation for Ventricular Arrhythmias: Insights From a Large Health System Registry in the United States
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。